PTGER3 knockdown inhibits the vulnerability of triple-negative breast cancer to ferroptosis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Prostaglandin E receptor 3 (PTGER3) has diverse biological roles and is implicated in various cancers.
• The specific function of PTGER3 in triple-negative breast cancer (TNBC) is not well-understood.

Purpose of the Study:

• To investigate the role of PTGER3 in the development and progression of TNBC.
• To explore PTGER3 as a potential therapeutic target and biomarker for TNBC.

Main Methods:

• Analysis of PTGER3 expression in TNBC patient samples.
• In vitro and in vivo experiments to assess the effects of PTGER3 on TNBC cell behavior.
• Investigation of PTGER3's impact on ferroptosis, epithelial-mesenchymal transition, and drug sensitivity.

Main Results:

• Low PTGER3 expression correlates with poor prognosis in TNBC patients.
• PTGER3 significantly influences TNBC cell invasion, migration, and proliferation.
• PTGER3 upregulation promotes ferroptosis by repressing glutathione peroxidase 4 (GPX4) and enhances paclitaxel sensitivity.
• PTGER3 downregulation inhibits ferroptosis via increased GPX4 and PI3K-AKT pathway activation.

Conclusions:

• Low PTGER3 expression promotes TNBC progression by protecting cells from ferroptosis.
• PTGER3 is a critical regulator of TNBC cell phenotypes and ferroptosis.
• PTGER3 presents a promising novel biomarker and therapeutic target for TNBC treatment.